Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People Briefs

Executive Summary

Cogentix Medical appoints permanent president and CEO following proxy fight; TeraRecon announces CEO and new executives; Millar Names CEO; Novadaq founder tapped as CEO; and other recent executive moves in the medtech space.

You may also be interested in...



Neuromodulation Devices Stimulate Opportunities In Urology

Neuromodulation for urological indications, notably overactive bladder (OAB), has been dominated since the late 1990s by Medtronic’s sacral-nerve stimulation system InterStim, with the more recent addition of Cogentix Medical’s Urgent PC for tibial nerve stimulation. Yet only a fraction of OAB patients receive effective neuromodulation treatment, and several companies hope to lower barriers to this modality by developing alternative devices for urological indications.

CMS Proposes DME Rule For Diabetic CGMs, Home-Use Infusion Pumps

More external infusion pumps used in the home and continuous glucose monitors for diabetics would be reimbursed under a proposed Medicare agency rule.

Device Week, 30 October 2020 – Medtech Money Influences US Elections; User-Fee Negotiations Kick Off

In this week’s podcast we discuss which political candidates are getting campaign donations from the medtech industry in the 2020 US Senate and House elections, and where the FDA and other stakeholders – including the medtech industry – stand as device user-fee negotiations get underway.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel